Paulo de Resende, CEO of Laboratorios Grin-Lupin in Mexico, describes the current state of the Mexican pharmaceutical market and explains how the acquisition of Laboratorios Grin will help increase Lupin’s footprint in Latin America by bringing more expertise and R&D resources.
Could you please introduce yourself to our international audience as well as the main operations of Laboratorios Grin?
"Grin has been a successful acquisition because they have an excellent product portfolio as well as a solid brand image in Mexico."
